We assisted Evonik Venture Capital, a corporate venture arm of Evonik Industries AG, one of the world’s leading providers of specialty chemicals, in an investment in Finnish growth company Synoste. Synoste is a Finnish medical device company that is developing a next-generation of patient friendly implements for the correction of skeletal deformations. Synoste’s proprietary technology will act as a platform for a range of long and short bone, spinal, and craniomaxilofacial applications providing solutions for millions of patients and their families across the globe.

Evonik Venture Capital makes medium-term investments in startups and venture capital funds throughout the world, with a total investment volume of 100 million euros. They are a strategic investor that actively collaborates with its portfolio companies helping implement the Evonik open innovation strategy and leveraging the strengths of Evonik to drive growth at portfolio companies.

The C&S team was headed by Partner Sakari Lukinmaa from our PE&VC and Banking & Finance services and included Associates Lauri Kivikari from our M&A service and Hannu Häkkänen from our Employment service. Our transaction team was supported by experts from other services.